🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  2. VP-102

    Verrica Pharmaceuticals

    Common Warts

    phase 3 other active

    1 trial

  3. VP-102 - Cantharidin, Topical Film Forming Solution

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 3 other completed

    2 trials

  4. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  5. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  6. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  7. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  8. VRDN-001 10 mg/kg

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  9. VRDN-001 Phase 3 Cohort (THRIVE)

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  10. VRDN-003

    Viridian Pharma Ltd

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  11. VRDN-003

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule active

    3 trials

  12. VX-121/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    6 trials

  13. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 3 small molecule active

    1 trial

  14. VX-147 film-coated tablet, VX-147, Coated Placebo Tablet

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial

  15. VX-210

    Vertex Pharmaceuticals (Australia) Pty.

    Cervical Spinal Cord Injury

    phase 3 small molecule terminated

    1 trial

  16. VX-445/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  17. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  18. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  19. VX-509

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  20. VX-659/TEZ/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

  21. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  22. VX-661/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  23. VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 50 mg granules in sachet

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  24. VX-809

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources